ABSTRACT
Objective: To study the risk factors for prevalence of acute myocardial infarction (AMI) in young and middle-aged population. Methods: A prospective cohort study was conducted in 110100 subjects at the age of (18-98) years who received physical examination in Kailuan Group from 2012-06 to 2014-10. Based on the limitations of male≤53 years and female≤63 years, a total of 62367 subjects were enrolled in our study. The subjects were followed-up for 2 years by the end point event of AMI to analyze the risk factors ofAMI occurrence. Results: According to AMI occurrence at the follow-up period, the subjects were divided into 2 groups: AMI group, n=56 and Control group, n=62152. Compared with Control group, AMI group had increased BMI, SBP, DBP and elevated blood levels of LDL-C, TG; AMI group also showed the higher ratios of subjects with the history of diabetes and taking anti-hypertension medication. Cox proportional hazard regression analysis indicated that age (RR=1.37), male (RR=60.54), LDL-C (RR=1.12), and TG (RR=5.93) were the risk factors forAMI occurrence in young and middle-aged population, allP<0.05. Conclusion: Age, male gender, blood levels of LDL-C, and TG were the risk factors for AMI occurrence in young and middle-aged population.
ABSTRACT
ObjectiveTo evaluate the effect and safety of different thrombolytic therapies for acute cerebral infarction due to occlusion of middle cerebral artery(MCA).MethodsOne hundred and thirty-two cases of acute cerebral infarction in territory of MCA were randomly divided into 3 groups,all of which were treated with alteplase.Group A (48 cases) was treated by intra-venous therapy with alteplase,group B (43 cases) was treated by infusing alteplase at the site of the internal carotid artery,and group C(41 cases) was treated by infusing alteplase into the thrombus.The improvement of neurological function,complications and mortality rate were recorded and statistically compared,with analysis of variance for counting data of normal distribution,x2 test for quantitative data,and the mean difference was significant at the 0.05level.ResultsThe effective rates of group A,B and C at 2 h,24 h,2 w were 18.8％ (9/48),39.6％ ( 19/48),45.8％ (22/48) ;39.5％ (17/43),53.5％ (23/43),58.1％ (25/43) ;78.0％ (32/41),85.4％ (35/41 ),87.8％ (36/41)respectively.The effective rate of group C was obviously better than group A( x2 =12.809,9.979,9.289,P ＜ 0.01 ) and B (x2 =31.295,19.425,17.161,P ＜ 0.01 ) with statistical significance.The effective rate of group B was better than group A at 2 h after thrombolytic therapy with statistical significance (x2 =4.801,P ＜ 0.05 ).The effective rate of group A and B did not have significant difference at 24 h,2 w after therapy ( x2 =1.765,1.375,P ＞ 0.05 ).The hemorrhage rates of group A,B and C were 14.6％ (7/48),14.0％ (6/43),7.3％ (3/41 ),the mortality rates of group A,B and C were 6.2％ (3/48),4.6％ (2/43),2.4％ (1/41),and there was no significant difference among the 3 groups ( x2 =1.328,0.786,P ＞ 0.05 ).ConclusionIt is suggested that the thrombus-imbeded thrombolytic therapy is a better way in treating acute cerebral infraction due to occlusion of MCA for its rapid and better therapeutic effect.
ABSTRACT
BACKGROUND:Sirolimus and Paclitaxel-eluting stents are commonly used for clinical application.Sirolimus-eluting stent have been proved safely and effectively to treat acute myocardial infarction.However,the comparison between those two eluting stents has been less reported yet.OBJECTIVE:To compare the security and long-term efficacy between Sirolimus- and Paclitaxel-eluting stents to the treatment of ST-segment acute myocardial infarction via percutaneous transluminal coronary intervention.METHODS:A total of 354 patients with ST-segment acute myocardial infarction,including 259 males and 95 females,were administrated with Sirolimus- and Paclitaxel-eluting stents.All cases were randomly divided into Sirolimus-elutin9 stent group (n=213) and Paclitaxel-eluting stent group (n=141).Major adverse cardiovascular events were compared between the two groups during 1-year following up.RESULTS AND CONCLUSION:One-year following up indicated that there was no significant difference in recurrent myocardial infarction (1.5% vs.1.5%) and cardiac death (2.5% vs.3.0%) between the two groups.Radiography showed that there was no significant difference in restenosis rate (5.0% vs.4.5%) between the two groups.Inner diameter lose was (0.19±0.34) mm in the Sirolimus-eluting stent group and (0.19±0.37) mm in the Paclitaxel-eluting stent group,and there was no significant difference.Additionally,there was also no significant difference in major adverse cardiovascular events between the two groups (8.9% vs.9.1%,P>0.05),suggesting that both Sirolimus-and Paclitaxel-eluting stents were safe and effective to the treatment of ST-segment acute myocardial infarction via percutaneous transluminal coronary intervention.